A cutting-edge molecule

for a radiant skin tone

Skin brightening and Safety and efficacy Results in only 2

photoaging prevention together months
lightening Description Science
A new patented ingredient designed for skin The color of our skin is determined mainly by the
brightening applications that shows neither amount, distribution and type of melanin, a pigment
cytotoxic effects nor any irritation or sensitization produced by melanocyte cells in a process called
reaction. melanogenesis. Melanin synthesis takes place in
melanosomes, which contain specific enzymes
Appearance controlling the production of the pigments. The first
Powder. step of melanogenesis is mediated by tyrosinase,
a key enzyme that catalyses the first two reactions
INCI of melanin synthesis. Abnormal accumulation of
Dimethylmethoxy Chromanyl Palmitate. melanin is responsible for hyperpigmentations,
Preservative free. which could be a serious aesthetic problem.
chromabright® synthetic molecule is a new
Properties brightening active which acts by inhibiting
chromabright® synthetic molecule is a new active for tyrosinase activity. It fulfils all the desirable qualities
brightening the skin safely. It induces a significant for an ideal skin brightener: exhibits a considerable
lightening effect on the skin while also fighting lightening in vivo effect on the skin, has a completely
against photoaging. safe profile, shows stability in formulations and
possesses a photoprotective effect on human
Applications epidermal keratinocytes, helping to prevent the skin
chromabright® synthetic molecule can be incor- damage caused by UV radiation.
porated into cosmetic formulations such as
emulsions, oily sera and, in general, in any Dosage 0.1-0.5%
formulation containing oil or silicon phases where
a brightening skin effect is desired.

Solubility
Please refer to our technical documentation for
information about the solubility of the product.

www.lipotec.com
In vitro efficacy
1. TYROSINASE INHIBITION 37% inhibition
The potential inhibitory effect of chromabright®
synthetic molecule on tyrosinase activity of mushroom
was evaluated in two separate studies using mushroom or human tyrosinases and tyrosinase activity
kojic acid as positive control. chromabright® synthetic molecule was used at 1 mM in the and 25% of human
mushroom assay and at 0.25 mM in the human tyrosinase assay. tyrosinase activity

2. MELANOGENESIS INHIBITON ON HUMAN EPIDERMAL MELANOCYTES chromabright® synthetic

Primary human melanocytes (HEMn-DP) cell cultures were used to compare the molecule exhibits a
melanogenesis inhibition efficacy of hydroquinone, arbutin, magnesium ascorbyl better depigmenting
phosphate (MAP) and kojic acid respect to chromabright® synthetic molecule at the same effect than MAP, kojic
concentration (10 µM). After 20 days of culture, melanin concentration was determined acid and arbutin, and
and values were normalized with respect to the number of cells per well. similar to hydroquinone
% of melanin (pg/cell)

ec t ®
l

ne

id

in
ro

ac

ut
ol gh
no

e
nt

M
ul

rb
m bri
Co

jic
i
qu

A
Ko
tic a
he om
ro
yd

nt hr
H

sy c

chromabright® synthetic
Melanogenesis inhibition and cytotoxic
molecule did not affect
effect of chromabright® synthetic molecule
melanocyte growth, while
(10 µM, 200 µM) and hydroquinone (10 µM)
Hydroquinone cytotoxicity
were observed by optical microscopy.
was clearly observed
Control chromabright® Hydroquinone (10 µM)
synthetic molecule
(10 µM)
3. CELLULAR PHOTOPROTECTION 190% increase in
Test based on the determination of the cell viability
protective effect of chromabright® synthetic chromabright® synthetic
molecule when tested in the presence of a molecule helps to prevent
cytotoxic dose of simulated solar light. the skin-damaging
Control non-irradiated Control + UV chromabright® effects of UV radiation.
synthetic molecule
(47 µM) + UV

In vivo efficacy
1. BRIGHTENING EFFECT A cream containing 0.1%
A group of 20 Asian female volunteers, aged 18 to 46, applied a cream containing 0.1% chromabright® synthetic
chromabright® synthetic molecule on one side of the face twice a day and a placebo cream molecule induced a
on the other side for 60 days. The brightening effect was instrumentally evaluated by Chroma- significant brightening
meter and the parameters used were: L* (luminance) and ITAº (individual typological angle). effect after 30 and 60
days
Percentage variations of the L* Percentage variations of the ITAº

Placebo

chromabright®
synthetic molecule

30 days 60 days 30 days 60 days

2. DEPIGMENTING EFFECT 80% of the volunteers with

A dermatological evaluation was performed in 10 volunteers, aged 18 to 70, with melasma melasma and 77.8% with
and/or actinic lentigines. A cream containing 0.5% chromabright® synthetic molecule was lentigines experienced a
applied on their face and/or hands twice a day for 60 days. significant improvement
after 60 days
The trademarks referenced in this brochure are owned by The Lubrizol Corporation. While the claims and supporting data provided in this publication are believed to be reliable and they are
presented free and for guidance only, there are no warranties of any kind. All express and implied warranties are disclaimed. The recipient is solely responsible for ensuring that products marketed
to consumers comply with all relevant laws and regulation. LIPOTEC is the exclusive holder of the both industrial and intellectual property rights identified herein. Recipient of this publication
agrees to indemnify and hold harmless each entity of the LIPOTEC organization for any and all regulatory action arising from recipient’s use of any claims or information in this publication, Ed. 14B
including, but not limited to, use in advertising and finished product label claims, and not present this publication as evidence of finished product claim substantiation to any regulatory authority.
© 2013, 2014 The Lubrizol Corporation.
Isaac Peral 17 Pol. Industrial Camí Ral - 08850 Gavà (Barcelona) Spain - Tel +34 93 638 80 00 - commercial@lipotec.com All Rights Reserved.